ArticleCureus2026
Antimicrobial Susceptibility Pattern of Ceftriaxone-Sulbactam-EDTA Against Multidrug-Resistant Gram-Negative Bacilli From ICU Clinical Isolates.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Antibiotic therapy remains the mainstay for the management of bacterial infections. However, the rapid emergence of multidrug-resistant (MDR) organisms has become a major clinical concern, leading to limited treatment options and increased healthcare burden. Ceftriaxone-sulbactam-EDTA (CSE) is a cephalosporin-beta-lactamase inhibitor combination containing disodium edetate, an antibiotic resistance breaker that may help restore antibacterial activity against resistant Gram-negative organisms. This study aimed to evaluate CSE as a potential therapeutic option by assessing its susceptibility pattern against MDR-Gram-negative bacilli (GNB) isolated from intensive care unit patients. Material and methods A laboratory-based study was conducted on 92 MDR-GNB isolates from ICU patients at Krishna Charitable & Medical Research Centre, Karad, India. Clinical specimens, including urine, endotracheal tube secretions, sputum, pus/wound swabs, blood, and body fluids, were processed using standard microbiological methods. Bacterial isolates were identified, and antimicrobial susceptibility testing was carried out as per Clinical and Laboratory Standards Institute recommendations. Phenotypic detection of extended-spectrum beta-lactamase (ESBL), metallo-beta-lactamase (MBL), and AmpC beta-lactamase production was performed to characterize resistance mechanisms. Additionally, the susceptibility profile of MDR-GNB isolates to CSE and other commonly used antimicrobial agents was evaluated. Results The study analyzed a total of 92 MDR-GNB isolates. The highest number of isolates were observed in the 31-40 and 41-50 age groups, with male predominance. Urine was the most common specimen source, with 39 (42.39%) isolates, followed by endotracheal tube secretions, with 20 (21.74%), and sputum, with 11 (11.96%) isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.